Akt2, has recently gained in importance as a therapeutic target. Although a lot of effort is being put into the development of Akt2-specific inhibitors, to date, no such inhibitor is available. Our group has obtained an Akt2-specific nanobody that triggers mitophagy in breast cancer cells. It is our objective to further characterize this nanobody and determine its therapeutic effect.